The value of TOP2A, EZH2 and paxillin expression as markers of aggressive breast cancer: Relationship with other prognostic factors

European Journal of Gynaecological Oncology

Volumn 32, Issue 2, 2011, Pages 156-159

  Panousis, D ^a   Patsouris, E ^b   Lagoudianakis, E ^a   Pappas, A ^a   Kyriakidou, V ^a   Voulgaris, Z ^a   Xepapadakis, G ^a   Manouras, A ^a   Athanassiadou, A M ^b   Athanassiadou, P ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Breast cancer; EZH2; Paxillin; TOP2A; Tumor markers

Indexed keywords

ANTIBODY; DNA TOPOISOMERASE (ATP HYDROLYSING); ESTROGEN RECEPTOR; KI 67 ANTIGEN; PAXILLIN; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR EZH2; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER STAGING; CANCER SURGERY; CARCINOMA; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION; SMEAR; STAINING; TUMOR VOLUME;

ADULT; AGED; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PAXILLIN; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 79955694314     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Nelson H.D., Tyne K., Naik A., Bougatsos C., Chan B.K., Humphrey L.: "U.S. Preventive Services Task Force. Screening for breast cancer: an update for the U.S. Preventive Services Task Force". Ann. Intern. Med., 2009, 151, 727.
2. Nappi O., Carrillo G.: "Prognostic and predictive factors of breast carcinoma: Beyond hormonal receptors and HER2". Eur. J. Cancer, 2008, (suppl. 6), 1.
3. Tang P., Skinner K.A., Hicks D.G.: "Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready?". Diagn. Mol. Pathol., 2009, 18, 125.
4. O'Connor J.K., Hazard L.J., Avent J.M., Lee R.J., Fischbach J., Gaffney D.K.: "Topoisomerase II alpha expression correlates with diminished disease-free survival in invasive breast cancer". Int. J. Radial. Oncol. Biol. Phys., 2006, 65, 1411.
5. Raaphorst F.M., Meijer C.J., Fieret E., Blokzijl T., Mommers E., Buerger H. et al.: "Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene". Neoplasia, 2003, 5, 481.
6. Zhu L., Li Y.F., Chen W.G., He J.R., Peng C.H., Zhu Z.G., Li H.W.: "HER2 and topoisomerase IIalpha: possible predictors of response to neoadjuvant chemotherapy for breast cancer patients". Chin. Med. J. (Engl.), 2008, 121, 1965.
7. Kirmizis A., Bartley S.M., Farnham P.J.: "Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy". Mol. Cancer Ther., 2003, 2, 113.
8. Schaller M.D.: "Paxillin: a focal adhesion-associated adaptor protein". Oncogene, 2001, 20, 6459.
9. Bantis A., Gianopoulos A., Gonidi M., Liossi A., Aggelonidou E., Petrakakou E. et al.: "Expression of p120, Ki-67 and PCNA as proliferation biomarkers in imprint smears of prostate carcinoma and their prognostic value". Cytopathology, 2004, 15, 25.
10. Greene D.R., Taylor S.R., Wheeler T.M., Scardino P.T.: "DNA ploidy by image analysis of individuals foci of prostate cancer: a preliminary report". Cancer Res., 1991, 51, 4084.
11. Koss L.G., Melamed M.R., Koss L.G., Melamed M.R. (eds.): "Recognizing and classifying cells. Koss/diagnostic cytology". 5th edition, Philadelphia, Lippincott Williams and Wilkins, 2006, 119.
12. Werner M., Chott A., Fabiano A., Battifora H.: "Effect of formalin fixation and processing on immunohistochemistry". Am. J. Surg., 2000, 24, 1016.
13. Creager A.J., Geisinger K.R., Perrier N.D., Shen P., Shaw J.A., Young P.R. et al.: "Intraoperative imprint cytologic evaluation of sentinel lymph nodes for lobular carcinoma of the breast". Ann. Surg., 2004, 239, 61.
14. Aihara T., Munakata S., Morino H., Takatsuka Y.: "Touch imprint cytology and immunohistochemistry for assessment of sentinel lymph nodes in patients with breast cancer". Eur. J. Surg. Oncol., 2003, 29, 845.
15. Aihara T., Munakata S., Morino H., Takatsuka Y.: "Comparison of frozen sections and touch imprint cytology for evaluation of sentinel lymph nodes metastasis in breast cancer". Ann. Surg. Oncol., 2004, 11, 747.
16. Flens M.J., van der Valk P., Tadema T.M., Huysmans A.C., Risse E.K., van Tol G.A., Meijer C.J.: "The contribution of immunohistochemistry in diagnostic cytology. Comparisons and evaluation with immunohistochemistry". Cancer, 1990, 65, 2704.
17. "World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Breast and Female Genital Organs". Tavassoli F., Devilee P. (eds.), Lyon, IARC Press, 2003, 10.
18. Page D.L., Anderson T.J.: "Diagnosis histopathology of the breast". Edinburgh, Churchill Livingstone, 1987, 303.
19. "Cytology Subgroup of the National Coordinating Committee for Breast Cancer Screening Pathology. Guidelines for cytology procedures and reporting on fine needle aspirates of the breast". Cytopathology, 1994, 5, 316.
20. Nielsen K.V., Ejlertsen B., Møller S., Jørgensen J.T., Knoop A., Knudsen H., Mouridsen H.T.: "The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D". Acta Oncol., 2008, 47, 725.
21. Genestie C., Zafrani B., Asselain B., Fourquet A., Rozan S., Validire P. et al.: "Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: major importance of the mitotic count as a component of both grading systems". Anticancer Res., 1998, 18, 571.
22. Miyoshi Y., Kurosumi M., Kurebayashi J., Matsuura N., Takahashi M., Tokunaga E. et al.: "Topoisomerase IIalpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers" Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Cancer Lett., 2008, 8, 264, 44.
23. Fritz P., Cabrera C.M., Dippon J., Gerteis A., Simon W., Aulitzky W.E., van der Kuip: "H.c-erbB2 and topoisomerase IIalpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study". Breast. Cancer Res., 2005, 7, R374.
24. Pritchard K.I.: "Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer?". J. Clin. Oncol., 2009, 27, 3875.
25. Jacobs J.J., and van Lohuizen M.: "Polycomb repression: from cellular memory to cellular proliferation and cancer". Biochim. Biophys. Acta, 2002, 1602, 151.
26. Raaphorst F.M., Meijer C.J., Fieret E., Blokzijl T., Mommers E., Buerger H., Packeisen J., Sewalt R.A., Otte A.P., van Diest P.J.: "Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene". Neoplasia, 2003, 5, 481.
27. Collen K., Eide G.E., Arnes J., Stefansson I.M., Eide J., Braaten A. et al.: "Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer". Clin. Cancer Res., 2006, 12, 1168.
28. Pietersen A.M., Horlings H.M., Hauptmann M., Langerød A., Ajouaou A., Cornelissen-Steijger P. et al.: "EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer". Breast. Cancer Res., 2008, 10, R109.
29. Tang X., Milyavsky M., Shats I., Erez N., Goldfinger N., Rotter V.: "Activated p53 suppresses the histone methyltransferase EZH2 gene". Oncogene, 2004, 23, 5759.
30. Turner C.E., Glenney J.R. Jr, Burridge K.: "Paxillin: A new vinculin-binding protein present in focal adhesions". J. Cell. Biol., 1990, 111, 1059.
31. Ishino K., Kaneyama, Shibanuma M., Nose K.: "Specific decrease in the level of Hic-5, a focal adhesion protein, during immortalization of mouse embryonic fibroblasts, and its association with focal adhesion kinase". J. Cell. Biochem., 2000, 76, 411.
32. Lipsky B.P., Beals C.R., Staunton D.E.: "Leupaxin is a novel LIM domain protein that forms a complex with PYK2". J. Biol. Chem., 1998, 273, 11709.
33. Brown M.C., Curtis M.S., Turner C.E., Paxillin L.D.: "Motifs may define a new family of protein recognition domains". Nat. Struct. Biol., 1998, 5, 677.
34. Brown M.C., Perrotta J.A., Turner C.E.: "Identification of LIM3 as the principal determinant of paxillin focal adhesion localization and characterization of a novel motif on paxillin directing vinculin and focal adhesion kinase binding". J. Cell. Biol., 1996, 135, 1109.
35. Schaller M.D.: "FAK and paxillin: regulators of N-cadherin adhesion and inhibitors of cell migration?". J. Cell. Biol., 2004, 166, 157.
36. Hagel M., George E.L., Kim A., Tamimi R., Opitz S.L., Turner C.E. et al.: "The adaptor protein paxillin is essential fornormal development in the mouse and is a critical transducer of fibronectin signaling". Mol. Cell. Biol., 2002, 22, 901.
37. Yano H., Uchida H., Iwasaki T., Mukai M., Akedo H., Nakamura K. et al.: "Paxillin a and crk-associated substrate exert opposing effects on cell migration and contact inhibition of growth through tyrosine phosphorylation". Proc. Natl. Acad. Sci., USA, 2000, 97, 9076.
38. Vadlamudi R., Adam L., Tseng B., Costa L., Kumar R.: " Transcriptional up-regulation of paxillin expression by heregulin in human breast cancer cells". Cancer Res., 1999, 59, 2843.
39. Hicks D., Yoder B., Short S., Tso E., Choueiri T., Budd G. et al.: "The expression of the focal adhesion protein paxillin in breast cancer correlates with HER2 amplification and may help predict a better response to chemotherapy". Mod. Pathol., 2005, (suppl. 1), 36A.
40. Madan R., Smolkin M.B., Cocker R., Fayyad R., Oktay M.H.: "Focal adhesion proteins as markers of malignant transformation and prognostic indicators in breast carcinoma". Hum. Pathol., 2006, 37, 9.